Search

Your search keyword '"Trkola A"' showing total 1,091 results

Search Constraints

Start Over You searched for: Author "Trkola A" Remove constraint Author: "Trkola A"
1,091 results on '"Trkola A"'

Search Results

1. ART-DEX: A novel strategy to monitor broadly neutralizing antibody activity during antiretroviral therapy of HIV-1

2. How much should we sequence? An analysis of the Swiss SARS-CoV-2 surveillance effort

3. Exploring viral aetiology in upper respiratory tract infections: insights from metagenomic next-generation sequencing in Swiss outpatients before and during the SARS-CoV-2 pandemic

4. Trapping the HIV-1 V3 loop in a helical conformation enables broad neutralization

5. Africa-specific human genetic variation near CHD1L associates with HIV-1 load

12. Assessing immunogenicity barriers of the HIV-1 envelope trimer

13. Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection

14. Assessing immunogenicity barriers of the HIV-1 envelope trimer

15. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

16. Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1

17. Long-term course of neutralising antibodies against SARS-CoV-2 in vaccinated and unvaccinated staff and residents in a Swiss nursing home: a cohort study 2021–2022

19. Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells

20. Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases

21. Viral suppression and retention in HIV care during the postpartum period among women living with HIV: a longitudinal multicenter cohort study

22. Viral suppression and retention in HIV care during the postpartum period among women living with HIV: a longitudinal multicenter cohort studyResearch in context

23. Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods

24. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

25. Author Correction: Africa-specific human genetic variation near CHD1L associates with HIV-1 load

27. Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection

28. High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus

29. Long-term course of neutralising antibodies against SARS-CoV-2 in vaccinated and unvaccinated staff and residents in a Swiss nursing home: a cohort study 2021–2022

30. Bridging the Gap: identifying factors impacting mRNA SARS-CoV-2 vaccine booster response in people living with HIV-1

33. Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization

35. Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity

36. Evolution of SARS-CoV-2 seroprevalence and clusters in school children from June 2020 to April 2021: prospective cohort study Ciao Corona

37. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response

38. How much should we sequence? An analysis of the Swiss SARS- CoV-2 surveillance effort

39. Viral suppression and retention in HIV care during the postpartum period among women living with HIV: a longitudinal multicenter cohort study

40. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation

41. Seroprofiling of Antibodies Against Endemic Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 in a Human Immunodeficiency Virus Cohort in Lesotho: Correlates of Antibody Response and Seropositivity

42. Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods

45. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

46. SCH-C (SCH 351125), An Orally Bioavailable, Small Molecule Antagonist of the Chemokine Receptor CCR5, is a Potent Inhibitor of HIV-1 Infection in vitro and in vivo

47. Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2).

49. Seroprofiling of antibodies against endemic human coronaviruses and SARS-CoV-2 in an HIV cohort in Lesotho: correlates of antibody response and seropositivity

50. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

Catalog

Books, media, physical & digital resources